← Atlas Theme · spans 1 topics
Obesity drug market share is won or lost at the PBM formulary gate.
Even the most clinically advanced metabolic therapies cannot scale successfully without establishing preferred, low-restriction placement on major PBM commercial formularies.
1
Topics it spans
3
Findings citing it
—
Evidence window
The convergence
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
GLP-1 Cross-Sector Effects
Eli Lilly's Market Leadership: Overall Obesity Dominance Intact, but Oral Foundayo Lags as Generic Tirzepatide Threat Looms Lilly's sluggish debut for its oral formulation is structurally linked to an early lack of standard commercial PBM coverage.
GLP-1 Cross-Sector Effects
CVS Caremark Restores Zepbound Coverage and Adds Foundayo Pill, Erasing Novo's Formulary Advantage Restoring preferred status across the big three PBMs acts as the primary driver of commercial sales acceleration and market parity.
GLP-1 Cross-Sector Effects
Novo Nordisk's Oral Dominance: Wegovy Pill Commands 89% of New Oral Weight-Loss Market, Offsetting Total Share Pressures Novo's massive oral market dominance over Lilly's similar candidate is largely attributed to establishing immediate, unhindered PBM formulary coverage.